Pubmed: Antagonism of 5-HT7 Receptors as a Promising Target for Gastric Cancer via Apoptotic Pathway
| dc.contributor.author | Cinar, I. | |
| dc.contributor.author | Dincer, B. | |
| dc.contributor.author | Cadirci, E. | |
| dc.contributor.author | Kara, S. | |
| dc.contributor.author | Yildirgan, M.I. | |
| dc.contributor.author | Halici, Z. | |
| dc.contributor.author | Yucelik, S.Z.P. | |
| dc.date.accessioned | 2025-08-21T08:10:05Z | |
| dc.date.issued | 2025 | |
| dc.description.abstract | Although current treatment strategies have improved clinical outcomes for gastric cancer, they present a challenging prognosis that necessitates novel therapeutic approaches. The 5-HT7 receptor, a member of the serotonin receptor family, plays a significant role in influencing the pathogenesis of various cancer types. This study seeks to investigate the complex interactions among 5-HT7 receptors, gastric cancer, and apoptotic processes. A comprehensive set of experimental techniques was employed, including in vitro staining assays for apoptosis assessment, real-time PCR, and cell proliferation assays. The findings indicate that the 5-HT7 receptor agonist enhances the proliferation of primary gastric tissue cancer cells and KATO-III cells, whereas treatment with the 5-HT7 receptor antagonist significantly inhibits cellular proliferation. Analysis of 5-HT7 receptor mRNA expression in gastric cancer patient populations indicated significantly elevated levels in cancerous tissues when compared to those in healthy tissues. The administration of a 5-HT7 receptor agonist (LP44) resulted in increased cell proliferation in primary gastric cancer cells and KATO-III cell lines, whereas treatment with a 5-HT7 receptor antagonist (SB-269970) significantly inhibited proliferation. Additionally, KATO-III cells treated with the 5-HT7 receptor antagonist demonstrated a marked upregulation of caspase-3, caspase-9, and BAX gene mRNA levels. In contrast, treatment with the 5-HT7 receptor antagonist was associated with a significant reduction in the expression of nuclear factor kappa B and 5-HT7 receptor mRNA levels. Annexin V-FITC/PI and Hoechst 33342 staining demonstrated a pronounced apoptotic effect through antagonism of 5-HT7 receptors compared to other groups. Collectively, the findings of this study suggest that the enhanced expression of 5-HT7 receptors influences gastric cancer formation by regulating the apoptotic axis. This provides a novel perspective for understanding the molecular mechanisms underlying the potential of 5-HT7 receptors as a targeted approach for combating gastric cancer via the apoptotic pathway. | |
| dc.identifier.doi | 10.1002/jbt.70326 | |
| dc.identifier.issue | 6 | |
| dc.identifier.pubmed | 40488271 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12597/34676 | |
| dc.identifier.volume | 39 | |
| dc.language.iso | en | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | 5‐HT7 receptors | |
| dc.subject | KATO‐III cells | |
| dc.subject | LP44 | |
| dc.subject | SB‐269970 | |
| dc.subject | caspase | |
| dc.title | Antagonism of 5-HT7 Receptors as a Promising Target for Gastric Cancer via Apoptotic Pathway | |
| dc.type | Article | |
| dspace.entity.type | Pubmed | |
| person.identifier.orcid | 0000-0003-0836-7205 | |
| person.identifier.orcid | 0000-0002-6239-6114 |
